Best Life Sciences Companies in Woburn, United States
The 59 best Life Sciences companies in Woburn, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ABclonal Biotechnology.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Woburn
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ABclonal Biotechnology Developer of protein and peptide reagents and kits for cell and molecular biology research | $281M | 55 mo ago | 12 | 2006 | — | Series D | — | — |
| 2 | Barricaid Provider of annular closure implants for the treatment of lumbar disc herniations | $197M | 31 mo ago | 49 49 → 91 (+86%) | 2006 | Jacob Einhorn Co-Founder & Chief Technology Officer | Series E | — | — |
| 3 | Intrinsic Therapeutics Reconstruction solutions for spinal disc defects | $139M | 110 mo ago | 49 | 2000 | Cary Hagan CEO & President | Series D | — | — |
| 4 | BioVex Oncolytic virus to treat cancer. | $133M | 200 mo ago | 75 | 1999 | — | Acquired | 3 patents Patents concentrated in chemistry & materials | — |
| 5 | EarlySense Developer of smart devices for cardiac health monitoring | $124M | 90 mo ago | 53 | 2004 | Avner Halperin Co-founder and Board member | Deadpooled | — | — |
| 6 | Myriant Manufacturing bio based chemicals from renewable feedstocks | $65M | 168 mo ago | 52 | 2005 | — | Series B | 176 patents Patents concentrated in chemistry & materials | — |
| 7 | Flexion Therapeutics Developer of therapies for the treatment of musculoskeletal disorders | $62M | 109 mo ago | 692 | 2007 | — | Acquired | — | — |
| 8 | Biotrove Provider of micro and nano-scale technology platforms for life science and drug discovery research… | $62M | 205 mo ago | — | 1997 | Albert Luderer ex-CEO | Acqui-Hired | 44 patents Microfluidic high‑throughput bioassay platforms for pathogen detection and sample handling | — |
| 9 | Predix Pharmaceuticals Small-molecule drugs that target G-protein coupled receptors (GPCRs) and ion channels to treat CNS diseases. | $59M | 257 mo ago | 26 | 2000 | — | Acquired | — | — |
| 10 | Terrestrial Developer of a microarray patch platform for therapeutic delivery 42Funding top 23%Talent bottom 49%Global bottom 33% All 3 signals ▾Fundingtop 23% Talentbottom 49% Globalbottom 33% Funding: Raised $57.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 42/100 | $57M | 4 mo ago | — | 2011 | Kathryn Kosuda Co-Founder & CSO | Series C | — | — |
| 11 | Courtagen Provider of solutions for neurological & metabolic disorders | $41M | 133 mo ago | 128 | 2009 | — | Deadpooled | — | — |
| 12 | NanoMosaic Manufacturer of system for early disease detection and prognosis 53Innovation top 32%Patents top 33%Funding top 34%Moat bottom 49% All 6 signals ▾Innovationtop 32% Patentstop 33% Fundingtop 34% Moatbottom 49% Marketbottom 46% Globalbottom 35% Innovation: 19 patents (top 52% of patent-holders) · 14 filings since 2022 vs 5 in 2017-21 Patents: 19 patents matched (strict assignee match) · 14 filings since 2022 vs 5 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $41M | 8 mo ago | 37 | 2018 | — | Series A | 19 patents Nanostructured biosensors for viral particle detection and unbiased proteomic analysis | — |
| 13 | Mitra Biotech Biotechnology company focused on advancing personalized cancer treatment through its clinically validated… | $41M | 118 mo ago | — | 2010 | Mallik Sundaram Co-Founder | Series B | — | — |
| 14 | AdvanDx Consumer Diagnostic Kits | $37M | 135 mo ago | 25 | 2002 | — | Acqui-Hired | 113 patents Point‑of‑care diagnostic sample preparation, ultrasonic lysis, and microscopic pathogen analysis | — |
| 15 | Excelimmune Immunity reagents and assay development for molecular diagnostics and drug discovery | $30M | 174 mo ago | 1 | 2006 | — | Series B | 22 patents Patents concentrated in chemistry & materials | — |
| 16 | Pathogenetix Developer of an automated system for rapid bacterial strain typing from complex samples | $28M | 152 mo ago | 29 | 1997 | Hamid Shirkhan President /Ceo | Deadpooled | 26 patents Automated biological sample prep and nucleic acid extraction/analysis platforms | — |
| 17 | ArQule Develops cancer therapeutics using a Kinase inhibitor platform | $25M | 104 mo ago | 32 | 1993 | — | Acquired | 764 patents Design and synthesis of heterocyclic small‑molecule therapeutics for oncology and proliferative diseases | — |
| 18 | Neurometrix Developer of non-invasive medical devices for pain and neurological disorders | $15M | 121 mo ago | 26 | 1996 | Shai Gozani Founder & CEO | Acquired | 186 patents Patents concentrated in health & consumer products | — |
| 19 | MarvelBiome Developer of novel therapeutics using microbiome | $13M | 9 mo ago | 9 | 2019 | Priti Chatter Co-Founder | Series C | 87 patents Therapeutic microbiome formulations for metabolic, neurodegenerative, and longevity applications. | — |
| 20 | Modular Genetics Developer of a proprietary, automated system for gene engineering and molecular biology | $9M | 118 mo ago | 7 | 2000 | — | Series B | 57 patents Biocatalytic synthesis of acyl‑modified amino acids and alcohols for specialty chemicals | — |
| 21 | Shaser Laser and light-based aesthetic medical devices | $8M | 195 mo ago | 15 | 2004 | Steven M. Fraundorfer CEO | Acquired | 106 patents Patents concentrated in health & consumer products | — |
| 22 | NanoHive Developer of spinal interbody fusion implants | $7M | 23 mo ago | 15 15 → 18 (+20%) | 2014 | Patrick O’Donnell CEO | Series C | — | 2 partnerships |
| 23 | ClearLine MD Air detection system for IV lines to prevent air embolism | $6M | 102 mo ago | 2 | 2016 | — | Series A | 7 patents Detecting and eliminating gas bubbles in intravenous infusion lines | — |
| 24 | Claros Diagnostics Lab-on-a-chip for diagnostic tests | $4M | 207 mo ago | 6 | 2009 | David Steinmiller Co-Founder & COO | Acquired | 24 patents Microfluidic sample analysis platforms with integrated fluid control and optical detection. | — |
| 25 | CryoXtract Instruments Developer of frozen aliquotting solutions | $4M | 168 mo ago | 15 | 2008 | — | Series A | — | — |
| 26 | Covaris Sample preparation solutions for genomics, proteomics, and drug discovery | $3M | 86 mo ago | 102 102 → 146 (+43%) | 1998 | — | Acquired | 193 patents Focused acoustic energy for sample preparation and enrichment of proteins and metabolites. | — |
| 27 | Anthill Technologies Applied chemistry operating system and chemical discovery engine | $3M | 214 mo ago | 3 | 2005 | Joseph Hogan Founder | Series A | 4 patents Decentralized real-time collaborative state synchronization for mobile ad‑hoc networks | — |
| 28 | SeqLL Provider of single-molecule sequencing technology for RNA and DNA | $2M | 65 mo ago | 7 | 2013 | — | Public | 6 patents Single‑molecule chromatin and nucleosome profiling with plasma protein analysis | — |
| 29 | Qlibrium Provider of on‑body drug delivery systems | $2M | 103 mo ago | 3 | 2014 | — | Funding Raised | — | — |
| 30 | CellMosaic Innovator in bioconjugation and crosslinking technologies for research, diagnostics, therapeutics | $1M | 134 mo ago | 1 | 2008 | Yumei Huang Founder | Funding Raised | 27 patents Design of branched sugar‑alcohol crosslinkers for therapeutic bioconjugates and polymer synthesis | 1 launch |
| 31 | EvoDenovo Developer of therapeutics for pain management | $1M | 50 mo ago | — | 2020 | Sid Labed CEO | Funding Raised | — | — |
| 32 | Pluromed Internal vessel occluder for clampless vascular and cardiovascular surgery | $1M | 172 mo ago | — | 2003 | Alexander Schwarz Co-Founder | Acqui-Hired | 83 patents Thermoresponsive polymer technologies for fluid control, hemostasis, and lithotripsy devices | — |
| 33 | AR Pharma Monoclonal antibody to treat B-cell chronic lymphocytic leukemia | $410K | 117 mo ago | 2 | 2015 | Rajah Menon CEO and Founder | Funding Raised | 248 patents Oral potassium‑binding agents using zirconium silicate for hyperkalemia treatment | — |
| 34 | MSM Protein Technologies Antibody drug discovery company targeting integral membrane proteins and GPCRs | $392K | 81 mo ago | 4 | 2005 | Davis Farmer Chairman of the Board and Co-Founder | Funding Raised | 15 patents Therapeutic monoclonal antibodies targeting chemokine receptors CXCR4, CCR7, and CCR6 | — |
| 35 | Intelon Optics Provider of smart technology for the treatment of cornea & other ocular structures related to eye health | $100K | 10 mo ago | 15 | 2011 | Dimitri Chernyak CEO | Early Stage | 22 patents Non-contact optical biomechanical analysis of reproductive cells and related spectroscopy systems | — |
Top 12 Life Sciences companies in Woburn
#1
Series C · Woburn, Massachusetts · founded 2011$57.3Mraised▾
Developer of a microarray patch platform for therapeutic delivery. The platform uses dissolvable tips made from advanced biomaterials for dose delivery and control. It aims to transform the delivery of therapies, offering a more convenient and comfortable patient experience. The platform seeks to eliminate the need for needles and refrigeration.
- Mar 2026Series C$57.3M
#2
Series A · Woburn, Massachusetts · founded 2018 · 37 employees$40.8Mraised▾
Manufacturer of system for early disease detection and prognosis
- Nov 2025Series A$3M
- Feb 2025Series A$1M
- Dec 2021Series A$40.8M
#3
Series C · Woburn, Massachusetts · founded 2019 · 9 employees$13.1Mraised▾
Developer of novel therapeutics using microbiome. The company helps in the isolation, identification, and characterization of microbial populations using assay methods and bacterial genetic approach for the development of novel therapeutics.
- Oct 2025Series C$39.6M
- Aug 2023Series B$10M
- Nov 2020Series A$3.1M
#4
Series E · Woburn, Massachusetts · founded 2006 · 49 employees$197.1Mraised▾
Provider of annular closure implants for the treatment of lumbar disc herniations in primary discectomy patients with large defects. The barricaid system includes two annular implants an occlusion and anchor components. Given the level-I clinical evidence that Barricaid reduces symptomatic recurrent herniation by 52% and associated reoperations by 61% for this population.
- Nov 2023Series E$55.5M
- Aug 2023Series E$5.5M
- Apr 2021Series E$38.4M
- Apr 2019Series E$52M
#5
Series C · Woburn, Massachusetts · founded 2014 · 15 employees$7Mraised▾
Developer of spinal interbody fusion implants. The company uses proprietary, biomimetic soft titanium technology to develop 3D printed spinal interbody fusion devices for surgical procedures. The product portfolio of the company inlcude cervical implants, Transforaminal lumbar interbody fusion (TLIF) implants, and Anterior lumbar interbody fusion (ALIF) implants.
- Aug 2024Series C$7M
- Dec 2023Venture Debt—
- Apr 2022Seed—
#6
Series D · Woburn, Massachusetts · founded 2006 · 12 employees$281.2Mraised▾
ABclonal Biotechnology manufactures protein reagents and kits for cell and molecular biology research. The company's products include a wide range of monoclonal, polyclonal, native or modified primary as well as tagged secondary antibodies, catalog and custom recombinant proteins, ELISA kits and gene clones. The company also provides peptide synthesis, peptide libraries, peptide modification, GMP peptide, glycopeptide and PNA services, custom antibody development, and protein expression services in bacterial, insect, yeast or mammalian cells.
- Dec 2021Series D$188.3M
- 2020Series C$92.9M
#7
Early Stage · Woburn, Massachusetts · founded 2011 · 15 employees$100Kraised▾
Intelon is a provider of smart technology for the treatment of cornea & other ocular structures related to eye health. It has developed BOSS a unique technology to assess biomechanical properties of the cornea and other critical eye diseases. It uses tomographic imaging that is used to determine thickness, curvature and other morphological parameters to assess structural dimensions form and shape of the cornea.
- Sep 2025Grant (prize money)$566.3K
- Jan 2025Grant (prize money)$1.2M
- Jun 2018Grant (prize money)$1.4M
#8
Deadpooled · Woburn, Massachusetts · founded 2004 · 53 employees$124Mraised▾
EarlySense is a developer of smart devices for cardiac health monitoring. The company has developed a sensor by using signal-processing technology that can be placed under the mattress to monitors body vitals, patient motion, and quality of sleep. All the information is relayed to a central panel or handheld device for proactive patient healthcare. The monitoring system can be integrated with a third-party system or devices. Its contact-free monitoring system is FDA-cleared and CE-approved.
- Jan 2019Series H$39M
- Jun 2016Series G$25M
- Apr 2015Series F$5M
- Jan 2015Series F$20M
#9
Series D · Woburn, Massachusetts · founded 2000 · 49 employees$138.7Mraised▾
Intrinsic Therapeutics produces the Barricaid Prosthesis for Partial Annulus Replacement. It is an implantable device designed to reduce the risk of reherniation through the annular defect after limited discectomy, a surgical procedure performed to correct disc herniation. The surgeon often relieves the pressure on the nerve by removing the bulging nuclear material. However, this creates a weakness or hole in the annulus through which herniation can potentially occur again. The Barricaid prosthesis reinforces the weakened part of the annulus and reduces the risk of reherniation.
- May 2017Venture Debt$21M
- May 2017Series D$28M
- Dec 2016Series C$17.9M
- Sep 2014Series C$17.2M
#10
Acquired · Woburn, Massachusetts · founded 1999 · 75 employees$133.3Mraised▾
BioVex was focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company's cancer program, OncoVEXGM-CSF, is an oncolytic virus or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti-tumor immune response.
- Nov 2009Series F$30M
- Mar 2009Series F$40M
- Nov 2007Series E$35M
- Oct 2003Series C$28.3M
#11
Series B · Woburn, Massachusetts · founded 2005 · 52 employees$65Mraised▾
Myriant is a subsidiary of PTT Global Chemical Public Company Limited, Thailand's largest chemical company. The company is manufacturing and commercializing bio-based chemical intermediates with a focus on bio-succinic acid, bio-butanediol and bio-acrylic acid which reduces carbon foot print. Myriant has received an award of up to $50 million from the U.S. Department of Energy to help finance a renewable biochemicals facility in Louisiana. It uses metabolic engineering to regulate the metabolic pathway of the microorganism leading to high yield of desired product.
- Jun 2012Conventional Debt$25M
- Jan 2011Series B$60M
- Nov 2010Conventional Debt$500K
- Aug 2010Conventional Debt$3M
#12
Acqui-Hired · Woburn, Massachusetts · founded 1997$61.9Mraised▾
Provider of micro and nano-scale technology platforms for life science and drug discovery research applications. Its flagship Open Array platform enabled researchers to run up to 3000 qPCR genotyping and/or gene expression assays simultaneously.
- Jun 2009Series B$13.3M
- Sep 2008Convertible Debt$22.7M
- Apr 2008Grant (prize money)$473.7K
- Jul 2007Grant (prize money)—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18113
- UNIV California17975
- Regeneron Pharma16083
- Amgen10515
- Monsanto Technology9755
- UNIV Pennsylvania8528
- Harvard College7464
- UNIV Texas7384
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.